Copegus Articles

Canada Seeks 75% Price Cut For Virazole

29 April 1996

Antivirals "Now 9% Of Anti-Infectives Market"

11 March 1996

ICN's Virazole Potential In Hep C

8 January 1996

Treatment Of Chronic Hepatitis: New Options

4 December 1995

ICN Pharma/Schering-P begin collaboration

18 September 1995

Intron A Gets Backing For Malignant Melanoma

7 August 1995

NEW YORK STOCK COMMENT

7 August 1995

Hantavirus Vaccine Immunogenic In Tests

5 June 1995

NEW YORK STOCK COMMENT

8 May 1995

ICN And A L Hit By Restructuring Charges

13 March 1995

Gilead's New Products Add To Impressive Pipeline

6 March 1995

NEW YORK STOCK COMMENT

27 February 1995

ICN Has Problems For Virazole Hep C Approval

27 February 1995

ICN Amends Virazole NDA

12 December 1994

Novel Approaches To RSV Infection

24 October 1994

First Efficacy Data On Glaxo's Neuraminidase Inhibitor For Flu

17 October 1994

Mixed Results From US Companies In 2nd Qtr

8 August 1994

HANTAVIRUS TRIAL IN USA

18 July 1994

VIRAZOLE REVIEW FOR HEPATITIS C TREATMENT

27 June 1994

VIRATEK SUBMITS VIRAZOLE NDA

13 June 1994

REVENUES COME IN FROM BETASERON AT CHIRON

14 March 1994

VIRATEK TO FILE NDA FOR VIRAZOLE

31 January 1994

RESPIGAM EFFECTIVE IN RSV, SAYS STUDY

29 November 1993

MEXICAN LAUNCH FOR SPI'S OSEUM

22 November 1993

VIRAZOLE FOR PEDIATRIC RSV

25 October 1993

SHAMAN PHARMA ON THE WARPATH

25 October 1993

ICN RELEASE DRUG TO US CDC

28 June 1993

VIRAZOLE LAUNCH IN LUXEMBOURG

15 March 1993

NEW YORK STOCK COMMENT

22 February 1993

VIRATEK OFFER

8 February 1993

VIRAZOLE APPROVED IN MEXICO

12 October 1992

LATEST US QUARTERLY RESULTS: MIXED SHOWING

8 June 1992

ICN-GALENIKA "HEALTHY SHARES"

6 April 1992

ICN-GALENIKA "HEALTHY SHARES"

6 April 1992

Showing 301-334 of 334 articles

Go to beginningPreviousNextGo to end